人民财讯1月26日电，据港交所披露，北京同仁堂（600085）医养投资股份有限公司向港交所提交上市 申请，保荐人为中金公司（601995）。 ...

Core Viewpoint - Gree Electric Appliances has strategically focused on chip research and development since 2015, establishing a comprehensive industrial chain capability from design to manufacturing [1] Group 1: Company Developments - In 2022, Gree established Zhuhai Gree Electronic Components Co., Ltd., which is responsible for the manufacturing of third-generation semiconductor silicon carbide (SiC) wafers, power device packaging testing, and semiconductor testing services [1] - The construction of the silicon carbide chip factory was initiated in December 2022 [1] Group 2: Business Model and Partnerships - Gree's external cooperation includes over 20 chip design companies, primarily focusing on a wafer foundry business model while also providing packaging and testing services [1] - The customer sectors include new energy vehicles, photovoltaic energy storage, industrial control, and home appliances, promoting the application of domestic silicon carbide chips in various scenarios [1]

浙海德曼(688577)1月26日晚公告，公司拟向特定对象发行股票募集资金总额不超过15.17亿元（含本 数），募集资金在扣除相关发行费用后的募集资金净额将全部用于高端复合化机床产业化项目、高端精 密机床与机器人硬件智造研发项目、补充流动资金。 浙海德曼专业从事数控车床研发、设计、生产和销售，致力于高精密数控车床的核心制造和技术突破， 自设立以来一直致力于现代化"工业母机"机床的研发、设计、生产和销售。公司现有高端数控车床、自 动化生产线、并行复合加工中心、普及型数控车床四大品类产品，主要应用于汽车制造、工程机械、通 用设备、航空航天、军事工业等行业领域。 高端数控机床具有加工精度更高、工作效率更高、空间复杂型面加工能力更强等技术优势，可有效满足 高端装备制造领域中众多复杂、精密零部件的加工制造要求，广泛应用于汽车制造、工程机械、通用设 备、机器人、航空航天、国防军工、半导体设备等下游产业。在我国制造业加速转型升级的过程中，高 端数控机床已成为我国高端装备制造业发展的重要基石。 浙海德曼表示，为满足下游客户复杂高精度、高效率加工需求，助力高端数控机床国产替代，深刻把握 市场发展机遇，公司通过本次募投项目的实施 ...

Core Insights - Tencent's CEO emphasized the importance of maintaining focus and a steady pace in response to AI-related anxieties, highlighting the company's unique characteristics and approach to innovation [1] - The introduction of "Yuanbao Pai," a new AI social feature, aims to enhance user interaction and entertainment within social contexts, integrating various Tencent services [1] - Tencent has made significant organizational changes to attract AI talent and enhance its AI capabilities, including the establishment of new departments and leadership roles [2] Group 1: AI Strategy and Development - Tencent is focusing on integrating large models and AI products, employing a collaborative design approach to enhance product and organizational development [3] - The company has rapidly scaled its AI assistant "Yuanbao," which has become one of the top AI applications in China, with frequent updates and integration across multiple Tencent platforms [2] - Tencent's AI strategy is characterized by a long-term investment approach, ensuring that its existing business strengths support ongoing AI development [3] Group 2: Business Performance and Future Outlook - Tencent's cloud business achieved significant profitability milestones in 2025, reflecting successful integration of AI-related products across various services [4] - The WeChat ecosystem remains a critical focus for Tencent, with ongoing efforts to enhance its features while balancing user needs and privacy concerns [3] - The Interactive Entertainment Group (IEG) has seen growth through innovation and content development, contributing to Tencent's overall business evolution [4][5]

人民财讯1月26日电，风范股份（601700）1月26日公告，公司与北京炎凌嘉业智能科技股份有限公司 (简称"炎凌嘉业")现有股东北京机器人产业发展投资基金(有限合伙)等签署了《股份收购协议》，公司 以自有及自筹资金3.825亿元收购炎凌嘉业51%股权。本次交易完成后，炎凌嘉业将成为公司的控股子 公司，并纳入公司合并报表范围。业绩承诺人承诺在业绩承诺期2026年、2027年、2028年内标的公司每 年合并报表归属于母公司所有者的税后净利润分别不低于人民币4000万元、6000万元、8000万元。若业 绩未达预期，业绩承诺赔偿金额上限是本次收购的交易收购价款总额。 ...

人民财讯1月26日电，亚信安全(688225)1月26日公告，公司于近日收到政府补助680万元，属于与收益 相关的政府补助。 ...

人民财讯1月26日电，格科微(688728)1月26日公告，持股6.34%的股东Hopefield Holding Limited(简 称"Hopefield")拟通过集中竞价交易或大宗交易方式减持其所持有的公司股份数量合计不超过500万股， 即合计减持不超过公司总股本的0.19%。 ...

Core Viewpoint - Kangyuan Pharmaceutical (600557) has received approval from the National Medical Products Administration for clinical trials of its product aimed at treating children's adenoid hypertrophy with spleen deficiency and phlegm obstruction, which could fill a clinical gap in this area [1] Group 1: Product Development - The approved product is a traditional Chinese medicine formulation designed to promote spleen function, resolve phlegm, and open the orifices [1] - Currently, there are no approved traditional Chinese medicines for treating children's adenoid hypertrophy, which primarily relies on chemical drugs such as nasal corticosteroids, leukotriene receptor antagonists, antihistamines, and immunomodulators [1] Group 2: Market Potential - The successful launch of this product could significantly enhance clinical value and address an unmet medical need in pediatric care [1]

Core Viewpoint - The company Sifang New Materials (605122) is expected to report a net loss of approximately 300 million yuan for the fiscal year 2025, indicating an increase in losses compared to the previous year [1] Financial Performance - The projected operating revenue for 2025 is around 1 billion yuan [1] - The decline in the real estate sector has significantly impacted the demand for the company's concrete products, with a reported 29.4% decrease in new construction area in Chongqing from January to December 2025 [1] Market Conditions - The primary market for the company's ready-mixed concrete is Chongqing, where the downturn in the real estate industry has led to a substantial reduction in product demand [1] - The cost of key raw materials for ready-mixed concrete has decreased at a slower rate than the selling prices, resulting in a decline in gross profit margins for the company's concrete sales [1]

人民财讯1月26日电，万东医疗（600055）1月26日公告，董事长马赤兵因个人原因申请辞去公司董事 长、董事、董事会战略委员会成员及召集人、董事会薪酬与考核委员会成员职务。离任后，马赤兵将不 在公司及控股子公司任职。1月26日，公司召开第十届董事会第十三次会议，选举王建国为第十届董事 会董事长，任期自公司第十届董事会第十三次会议审议通过之日起至公司第十届董事会任期届满之日 止。 ...